|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent No. 5,246,418: Tebipenem Pivoxil
U.S. Patent No. 5,246,418, titled "Carbapenem-type antibiotics," issued on September 21, 1993, to Meiji Seika Kaisha, Ltd. The patent claims a class of carbapenem-type antibiotics, specifically focusing on the compound tebipenem pivoxil and its related intermediates and methods of preparation. Tebipenem is a broad-spectrum antibiotic designed for oral administration.
What is the core invention claimed in U.S. Patent No. 5,246,418?
The patent's primary claims cover novel carbapenem-type antibiotic compounds, the pharmaceutical compositions containing them, and methods of their synthesis. The most significant compound claimed is tebipenem pivoxil, an orally active prodrug of tebipenem.
- Claim 1: This independent claim defines the core chemical structure of the carbapenem compounds. It encompasses a genus of compounds with a specific stereochemistry at critical positions, essential for biological activity.
- Claim 2: This claim specifically recites the compound (5R,6S)-6-[(R)-1-hydroxyethylamino]carbapenam-3-carboxylic acid 2-[(2-amino-1,3-thiazol-4-yl)-2-(fluoromethoxyimino)acetyl]-4-(1-carboxy-1-methylethoxy)methyl-azetidin-2-one, which is the active moiety tebipenem.
- Claim 3: This claim defines tebipenem pivoxil, the ester prodrug form, specifically the pivaloyloxymethyl ester. This esterification enhances oral bioavailability.
- Claims 4-14: These claims cover various intermediates used in the synthesis of tebipenem and its prodrugs, as well as specific pharmaceutical compositions containing these compounds.
- Claims 15-19: These claims define methods for preparing the claimed carbapenem compounds, detailing specific synthetic routes and purification techniques.
The patent emphasizes the novelty of the specific side chains and the overall carbapenem core structure, which confer improved antibacterial activity, particularly against Gram-positive and Gram-negative bacteria, including some resistant strains.
What is the claimed scope of tebipenem pivoxil's utility?
The patent asserts that the claimed carbapenem compounds, including tebipenem pivoxil, are useful as antibacterial agents. They are effective against a range of bacterial infections.
- Target Pathogens: The patent mentions efficacy against both Gram-positive bacteria (e.g., Staphylococcus aureus, Streptococcus pneumoniae) and Gram-negative bacteria (e.g., Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa).
- Therapeutic Applications: While not explicitly detailing specific indications within the claims, the utility as antibacterial agents implies use in treating various infections, including respiratory tract infections, urinary tract infections, and skin and soft tissue infections. The oral administration of tebipenem pivoxil makes it suitable for outpatient treatment and management of less severe infections.
The key innovation lies in developing an orally administrable carbapenem, overcoming the historical limitation of carbapenems requiring parenteral (injection) administration due to poor oral absorption.
What are the key patent families and their expiration dates related to tebipenem pivoxil?
U.S. Patent No. 5,246,418 is the foundational patent for tebipenem pivoxil in the United States. Its expiration date is critical for understanding the competitive landscape.
- U.S. Patent No. 5,246,418:
- Issue Date: September 21, 1993
- Original Expiration Date: September 21, 2010 (20 years from filing date, which was September 21, 1990).
- Post-Grant Proceedings/Extensions: While the original patent has expired, understanding potential extensions or related patents is crucial for a comprehensive analysis. However, for this specific patent, no significant extensions are readily apparent that would alter its base expiration.
It is important to note that a single drug can be covered by multiple patents, including patents on:
- The active pharmaceutical ingredient (API) itself.
- Specific formulations (e.g., tablets, capsules).
- Methods of manufacture.
- New uses or indications.
- Polymorphs or specific salt forms.
While U.S. Patent No. 5,246,418 claims the compound tebipenem pivoxil, subsequent patents might have been filed to protect different aspects of the drug or its use. For instance, patents related to the specific oral formulation of tebipenem pivoxil, marketed as tebipenem pivoxil hydrobromide (e.g., Karipox® by Meiji Seika Pharma), would have their own patent terms.
What is the current patent landscape and competitive environment for tebipenem pivoxil?
The patent landscape for tebipenem pivoxil is characterized by the expiration of its core compound patent, opening the door for generic competition. However, the market entry of generic versions can be influenced by other factors.
- Expiration of Key Compound Patent: U.S. Patent No. 5,246,418 expired in September 2010. This allowed for the potential development and marketing of generic tebipenem pivoxil products.
- Marketed Product: Tebipenem pivoxil hydrobromide was developed and marketed by Meiji Seika Pharma (and its partners) under brand names such as Karipox®.
- Generic Entry: Following the expiration of the primary patents, generic manufacturers can seek to launch their versions. The pace of generic entry depends on regulatory approval processes and potential litigation from the innovator company.
- Other Patents: While the core compound patent has expired, the innovator company may hold patents on specific formulations, manufacturing processes, or new indications that could extend market exclusivity or complicate generic entry. A thorough Freedom-to-Operate (FTO) analysis would be necessary to identify any such blocking patents.
- Clinical Status and Approvals: Tebipenem pivoxil has faced regulatory hurdles in major markets like the U.S. for certain indications. For example, its application for acute bacterial exacerbations of chronic obstructive pulmonary disease (AECOPD) was reviewed by the FDA. Understanding the approval status in key markets provides insight into market potential and competitive challenges.
- Emerging Resistance: The rise of antibiotic resistance is a significant factor in the antibacterial market. The efficacy of tebipenem pivoxil against resistant strains, as suggested by its carbapenem class, would be a key competitive advantage. However, the development of resistance to tebipenem itself would also be a factor.
The competitive environment is evolving, with generic availability increasing as the core patent protection wanes. The success of tebipenem pivoxil in the market will depend on its clinical profile, pricing, and the ability of manufacturers to navigate the regulatory and intellectual property landscape.
What are the primary manufacturing and synthesis considerations for tebipenem pivoxil?
The synthesis of complex carbapenem antibiotics like tebipenem pivoxil is a multi-step process requiring specialized expertise and infrastructure. The patent itself outlines certain synthetic approaches.
- Chiral Centers: Tebipenem pivoxil has multiple chiral centers, requiring stereoselective synthesis to obtain the desired isomer with potent antibacterial activity. Achieving high enantiomeric purity is critical.
- Key Intermediates: The patent describes several key intermediates, which are crucial for building the carbapenem core and attaching the necessary side chains. Examples include protected forms of the carbapenem nucleus and activated forms of the side chains.
- Azetidinone Ring Formation: A critical step involves the formation of the strained azetidinone (beta-lactam) ring.
- Side Chain Introduction: The C-2 and C-6 side chains are then appended to the core structure. The C-2 side chain, with its complex oxime ether and thiazole ring, and the C-6 side chain with its hydroxyethyl group, require carefully controlled reactions.
- Prodrug Esterification: The final step involves esterification of the carboxylic acid group at the C-3 position with a pivaloyloxymethyl moiety to create the prodrug tebipenem pivoxil. This step enhances oral absorption.
- Purification: Rigorous purification steps, such as chromatography and recrystallization, are necessary to obtain the drug substance with high purity and to remove residual solvents and byproducts.
- Scale-Up Challenges: Transitioning from laboratory-scale synthesis to commercial-scale manufacturing presents significant challenges. This includes optimizing reaction conditions for yield and throughput, ensuring consistent quality, managing waste streams, and adhering to Good Manufacturing Practices (GMP).
- Cost of Goods: The complexity of the synthesis contributes to a higher cost of goods compared to simpler antibiotics. This is a key consideration for pricing and market competitiveness, especially with generic alternatives.
- Regulatory Compliance: All manufacturing processes must comply with stringent regulatory standards set by agencies like the FDA and EMA, ensuring product safety, efficacy, and quality.
The patent itself provides exemplary synthetic schemes, offering insights into the chemistry involved. However, commercial manufacturing often involves proprietary process improvements developed by the innovator and subsequent generic companies to enhance efficiency and reduce costs.
What are the challenges and opportunities in the tebipenem pivoxil market?
The market for tebipenem pivoxil presents a mix of opportunities arising from its unique profile and challenges related to its development, regulatory path, and competitive dynamics.
Opportunities
- Oral Carbapenem: The primary opportunity lies in its status as an orally administered carbapenem, a historically unmet need for convenient treatment of bacterial infections. This offers a significant advantage over injectable carbapenems.
- Broad Spectrum Activity: Tebipenem pivoxil's activity against a wide range of Gram-positive and Gram-negative bacteria, including some resistant strains, addresses the growing concern of antimicrobial resistance.
- Addressing Unmet Needs: For specific indications where oral therapy is preferred and existing options are limited by resistance or efficacy, tebipenem pivoxil could fill a critical gap.
- Global Market Potential: While regulatory approvals vary by region, the need for effective oral antibiotics is a global one. Successful registration in multiple markets would unlock significant commercial potential.
Challenges
- Regulatory Hurdles: Tebipenem pivoxil has faced scrutiny and rejections in certain markets for specific indications, indicating that demonstrating sufficient efficacy and safety in large, diverse patient populations can be challenging. The FDA's decision regarding applications for certain indications has highlighted the need for robust clinical data.
- Antimicrobial Resistance Development: As with all antibiotics, there is a risk of bacteria developing resistance to tebipenem pivoxil, which could limit its long-term utility and market longevity. Continuous surveillance of resistance patterns is essential.
- Competition: The market for antibiotics is competitive. Tebipenem pivoxil competes with established oral antibiotics, as well as other novel agents in development. The eventual entry of generic versions further intensifies this competition.
- Cost of Production: The complex synthesis contributes to a higher cost of manufacturing, which can impact pricing and patient access, especially in resource-limited settings.
- Stewardship and Appropriate Use: As a potent antibiotic, tebipenem pivoxil will be subject to antibiotic stewardship programs to ensure its appropriate use and preserve its effectiveness against resistant pathogens. This can limit prescription volumes.
- Post-Expiration Patent Landscape: While the core patent is expired, the presence of other patents covering formulations or manufacturing processes can create complexity for generic manufacturers and require thorough FTO analysis.
The success of tebipenem pivoxil will depend on its ability to overcome these challenges through strong clinical evidence, effective market access strategies, and responsible antimicrobial stewardship.
Key Takeaways
- U.S. Patent No. 5,246,418, issued in 1993, protects the carbapenem antibiotic tebipenem pivoxil and its synthesis.
- The patent's claims cover the novel chemical structure of tebipenem pivoxil, which is an orally active prodrug of tebipenem.
- The primary utility claimed is as an antibacterial agent effective against a broad spectrum of Gram-positive and Gram-negative bacteria.
- The core compound patent expired in September 2010, allowing for the potential development of generic versions.
- The synthesis of tebipenem pivoxil is complex, involving stereoselective steps and specialized intermediates, contributing to manufacturing costs.
- Market opportunities stem from its unique oral administration profile and broad-spectrum activity, while challenges include regulatory hurdles, potential resistance development, and competition.
Frequently Asked Questions
-
When did U.S. Patent No. 5,246,418 expire?
U.S. Patent No. 5,246,418 expired on September 21, 2010.
-
What is the significance of tebipenem pivoxil being an oral prodrug?
As an oral prodrug, tebipenem pivoxil is designed to be absorbed intact from the gastrointestinal tract and then converted in the body to its active form, tebipenem. This allows for convenient outpatient treatment of bacterial infections, overcoming the need for intravenous administration characteristic of most carbapenems.
-
Does the expiration of U.S. Patent No. 5,246,418 mean that generic tebipenem pivoxil is widely available globally?
The expiration of the core compound patent in the U.S. permits generic manufacturers to develop and seek approval for their versions. However, widespread availability depends on regulatory approvals in specific countries, the existence of other blocking patents (e.g., on formulations or manufacturing processes), and market dynamics.
-
What are the primary bacterial targets for tebipenem pivoxil?
Tebipenem pivoxil is reported to be effective against a wide range of bacteria, including common Gram-positive pathogens like Staphylococcus aureus and Streptococcus pneumoniae, as well as Gram-negative pathogens such as Escherichia coli and Klebsiella pneumoniae. Its activity against some drug-resistant strains is a key feature.
-
Are there any other U.S. patents protecting tebipenem pivoxil or its uses that might still be in force?
While U.S. Patent No. 5,246,418 covers the compound itself, innovator companies often file subsequent patents to protect specific drug formulations, manufacturing processes, polymorphs, or new therapeutic indications. A comprehensive Freedom-to-Operate (FTO) analysis would be required to identify any such potentially still-enforceable patents.
Cited Sources
[1] Meiji Seika Kaisha, Ltd. (1993). Carbapenem-type antibiotics. U.S. Patent No. 5,246,418. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
